GPR35 agonist 3
Based on 1 Customer Validation
GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50value of 1.4 μM. GPR35 agonist 3 can be used for the research of various diseases, such as gastric cancer, type 2 diabetes, cardiovascular diseases, immune system and peripheral nervous system.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.32%
- CAS No.: 123021-85-2
- Formule: C12H9NO5S
- Masse moléculaire:279.27
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
EC50: 1.4 μM (GPR35)[1].
Ki: 0.0508 μM (GPR35)[1].
IC50: 0.349 μM (GPR35)[1].
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.349 μM
Compound: 3
|
Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay
Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay
|
[PMID: 23888932] |
| HEK-293T | EC50 |
1.4 μM
Compound: 3
|
Agonist activity at human GPR35 expressed in HEK293T cells at 5 uM by EYPF-based beta-arrestin-2 luciferase reporter gene assay
Agonist activity at human GPR35 expressed in HEK293T cells at 5 uM by EYPF-based beta-arrestin-2 luciferase reporter gene assay
|
[PMID: 23888932] |
In Vitro
GPR35 agonist 3 (compound 3) shows GPR35 agonist potency with an EC50 value of 1.4 μM[1].
GPR35 agonist 3 has affinity and potency for GPR35 with values of 0.0508 μM (Ki) and 0.349 μM (IC50)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 123021-85-2
-
Appearance Solid
-
Masse moléculaire 279.27
-
Formule C12H9NO5S
-
Color White to off-white
-
SMILES
O=C(O)COC1=CC=C(/C=C(SC(N2)=O)\C2=O)C=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
In Vitro:
DMSO : 125 mg/mL (447.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5808 mL | 17.9038 mL | 35.8076 mL | 89.5191 mL |
| 5 mM | 0.7162 mL | 3.5808 mL | 7.1615 mL | 17.9038 mL | |
| 10 mM | 0.3581 mL | 1.7904 mL | 3.5808 mL | 8.9519 mL | |
| 15 mM | 0.2387 mL | 1.1936 mL | 2.3872 mL | 5.9679 mL | |
| 20 mM | 0.1790 mL | 0.8952 mL | 1.7904 mL | 4.4760 mL | |
| 25 mM | 0.1432 mL | 0.7162 mL | 1.4323 mL | 3.5808 mL | |
| 30 mM | 0.1194 mL | 0.5968 mL | 1.1936 mL | 2.9840 mL | |
| 40 mM | 0.0895 mL | 0.4476 mL | 0.8952 mL | 2.2380 mL | |
| 50 mM | 0.0716 mL | 0.3581 mL | 0.7162 mL | 1.7904 mL | |
| 60 mM | 0.0597 mL | 0.2984 mL | 0.5968 mL | 1.4920 mL | |
| 80 mM | 0.0448 mL | 0.2238 mL | 0.4476 mL | 1.1190 mL | |
| 100 mM | 0.0358 mL | 0.1790 mL | 0.3581 mL | 0.8952 mL |
GPR35 agonist 3 Related Classifications
HY-131728 Related Classifications
Powered by Bioz